CCNE1 and triple-negative breast carcinoma: Accordingly, Chen et al. recently reported that cyclin E overexpression is a potential biomarker predicting response to AZD1775 monotherapy in triple-negative breast cancers (TNBCs) (Chen et al., 2018), results consistent with our study.